Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations. (15th November 2022)

• Record Type: Journal Article
• Authors: Morrill, Christie; Friesen, Westley J.; Babu, Suresh; Baiazitov, Ramil Y.; Du, Wu; Karloff, Diane B.; Lee, Chang-Sun; Moon, Young-Choon; Ren, Hongyu; Sierra, Jairo; Tomizawa, Yuki; Vazirani, Priya; Welch, Ellen M.; Xue, Xiaojiao; Zhuo, Jin
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 76(2022)
• Publication Date: 2022-11-15
• Subjects: Readthrough -- Premature termination codon -- Nonsense mutation -- Guanidine -- Myotube; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2022.128989
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Using small molecules to induce readthrough of premature termination codons is a promising therapeutic approach to treating genetic diseases and cancers caused by nonsense mutations, as evidenced by the widespread use of ataluren to treat nonsense mutation Duchene muscular dystrophy. Herein we describe a series of novel guanidino quinazoline and pyrimidine scaffolds that induce readthrough in both HDQ-P1 mammary carcinoma cells and mdx myotubes. Linkage of basic, tertiary amines with aliphatic, hydrophobic substituents to the terminal guanidine nitrogen of these scaffolds led to significant potency increases. Further potency gains were achieved by flanking the pyrimidine ring with hydrophobic substituents, inducing readthrough at concentrations as low as 120 nM and demonstrating the potential of these compounds to be used either in combination with ataluren or as stand-alone therapeutics.